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ABSTRACT
Low-grade systemic infl ammation is at the base of the 
most chronic non-communicable diseases, which are reaching 
epidemic proportions worldwide. Key players in the regula-
tion of infl ammation are n-6 and n-3 polyunsaturated fatty 
acids (PUFAs), in particular arachidonic acid (n-6) and ei-
cosapentaenoic acid (n-3). Th ey are precursors of eicosanoids 
- signaling molecules involved in modulating the intensity 
and duration of infl ammatory responses. Eicosanoids derived 
from n-6 PUFAs have proinfl ammatory actions, while those 
derived from n-3 PUFAs act anti-infl ammatory. Th erefore, 
dietary intake of n-6 and n-3 PUFAs, as well as their ratio, 
could markedly aff ect the pathogenesis and manifestation of 
many chronic diseases associated with low-grade infl amma-
tion. Th is review will focus on the relationship between dietary 
PUFAs and infl ammation, with reference to PUFAs status in 
plasma phospholipids in Serbian population.
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ABBREVIATIONS
AA - arachidonic acid
ALA - alpha-linolenic acid 
CRP - C-reactive protein
DGLA - dihomo-γ-linolenic acid
DHA - docosahexaenoic acid 
DPA - docosapentaenoic acid
DTA - docosatetraenoic acid
EPA - eicosapentaenoic acid
IL - interleukine
SAŽETAK
U osnovi većine hroničnih nezaraznih bolesti, koje širom 
sveta dostižu epidemijske razmere, leži „tiha“ infl amacija. 
Ključni igrač u regulaciji infl amacije su polinezasićene ma-
sne kiseline (PNMK) n-6 i n-3 familije, posebno arahidonska 
(n-6) i eikozapentaenska kiselina (n-3). One su prekursori ei-
kozanoida – signalnih molekula koji su uključeni u intenzi-
tet i trajanje infl amatornog odgovora. Eikozanoidi poreklom 
od n-6 PNMK deluju proinfl amatorno, dok oni poreklom 
od n-3 PNMK imaju anti-infl amatorno dejstvo. Zbog toga 
dijetarni unos n-6 i n-3 PNMK, kao i njihov odnos, može 
značajno da utiče na patogenezu i manifestaciju mnogih 
hroničnih oboljenja koja su povezana sa „tihom“ infl amaci-
jom. Ovaj pregledni rad se bavi vezom između unosa PNMK 
i infl amacije, sa osvrtom na status n-3 i n-6 masnih kiselina 
u fosfolipidima plazme u populaciji u Srbiji.
Ključne reči:  Polinezasićene masne kiseline, infl amaci-
ja, arahidonska kiselina, eiokozapentaenska kiselina, eiko-
zanoidi, citokini
LA - linoleic acid
LT – leukotrienes
NFκB - nuclear factor κ B
PG - prostaglandins 
PPAR - peroxisome proliferation activator receptor
PUFAs - polyunsaturated fatty acids
TX - thromboxanes 
TNF-α - tumor necrosis factor-α 
WHO - World Health Organisation
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Chronic non-communicable diseases, which include 
cardiovascular disease, type 2 diabetes, cancer and chronic 
respiratory conditions, are steadily increasing and the ma-
jor cause of death worldwide. A key player in the pathogen-
esis of most non-communicable diseases is low-grade in-
flammation, characterized by increased systemic levels of 
some cytokines and C-reactive protein (CRP). Low-grade 
systemic inflammation has been associated with obesity, 
atherosclerosis and type 2 diabetes (1).  Several factors 
may cause chronic inflammation, but the most important 
ones are unhealthy diet and sedentary lifestyle (2). Accord-
ing to the World Health Organization (WHO) the major 
nutritive risk factors for chronic diseases are high energy 
intake, high intake of total fats, saturated and trans fatty 
acids, cholesterol, refined carbohydrates and alcohol, with 
low intake of dietary fibers, antioxidants and n-3 polyun-
saturated fatty acids (PUFAs) (3). 
PUFAs are vitally important constituents of cell mem-
branes which maintain membrane fluidity, assure the op-
timal environment for function of membrane proteins and 
regulate many cellular functions (4). There are two prin-
cipal series of PUFAs: the n-3 and the n-6 families. They 
are physiologically and metabolically distinct and have dif-
ferent effects on human health. Precursors for synthesis 
of long-chain PUFAs are the 18-carbon fatty acids: lino-
leic acid (18:2n-6, LA) and alpha-linolenic acid (18:3n-3, 
ALA). They are essential fatty acids, which cannot be syn-
thesized by mammals and therefore have to be obtained 
from the diet (5). Once ingested, LA can be converted to 
other n-6 PUFAs, and ALA to n-3 PUFAs by the relevant 
desaturase and elongase enzymes. As a consequence, the 
relative dietary amounts of LA and ALA determine the 
relative cellular content of n-3 and n-6 PUFAs. Although 
the ratio of n-6/n-3 PUFAs in the diet should not exceed 
4, this ratio is typically 15-20 in the Western diet (6). This 
predominance of n-6 fat is due to the abundance in the diet 
of LA, which is present in high concentrations in soy, corn, 
safflower, and sunflower oils and in products made from 
these oils. By contrast, there is a low intake of n-3 PUFAs: 
ALA, which is present in leafy green vegetables, some nuts 
and in linseed and canola oils, as well as eicosapentaenoic 
(20:5n-3, EPA) and docosahexaenoic acid (22:6n-6, DHA) 
which are found in cold water fish (5). Since the most often 
consumed oil in Serbia is sunflower oil, with low intake of 
sea food and linseed oil (7), it can be assumed that the n-6-
/n-3 ratio in the diet is very high. 
LIPID AND PEPTIDE INFLAMMATORY
MEDIATORS
The clinical signs of inflammation, such as pain, red-
ness and swelling, result from the release of lipid (ei-
cosanoids) and peptide (cytokines) inflammatory me-
diators . In response to trauma or an acute infection by 
pathogens, the level of cytokines in the circulation will 
increase. The first cytokines as they appear are tumor 
necrosis factor-α (TNF-α), interleukines IL-1β, IL-6, IL-1 
receptor antagonist (IL-1ra), soluble TNF-α-receptors 
(sTNF-R), and IL-10 (2). Concentration of acute phase 
proteins from liver, such as CRP, rises as well. The eleva-
tion of cytokines in chronic low-grade inflammation is 
markedly lower than in an acute response: it is usually 
2-3 fold higher than physiological levels (8). Neverthe-
less, recent studies have shown that plasma levels of IL-6, 
TNF-α, and in particular CRP, can predict the risk of 
myocardial infarction (9-11). The stimuli for the produc-
tion of cytokines in chronic low-grade inflammation are 
still unknown, but the role of nutritional factor could not 
be excluded. Furthermore, the adipose tissue has been 
assumed as an origin of TNF-α in low-grade systemic in-
flammation (12). High levels of circulating TNF-α were 
found in people with type 2 diabetes, and its direct role 
in insulin resistance and metabolic syndrome was docu-
mented in several studies (13, 14). In contrast to TNF-α, 
in vivo studies provide little evidence on the involvement 
of IL-6 in metabolic syndrome. Moreover, IL-6 is classi-
fied as both pro- and anti-inflammatory cytokine, and its 
concentration is the first to increase in response to ex-
ercise, followed by increased levels of well-known  anti-
inflammatory cytokines IL-1ra and IL-10 (15). 
A series of findings showed that production of TNF-α 
and other cytokines can be modified by eicosanoids. Eico-
sanoids, which includes prostaglandins (PG), leukotrienes 
(LT) and thromboxanes (TX), are signaling molecules gener-
ated from 20 carbon PUFAs, mainly arachidonic acid (AA), 
by the metabolic processes summarized in Figure 1. The es-





derived from AA via cyclooxigenase and lipoxigenase-5 
enzymatic pathways (16). However, EPA as the n-3 homo-
logue of AA competes for the same enzymes and thus in-
hibit AA metabolism and suppress the generation of the 
n-6 inflammatory mediators (5). The relation between ei-
cosanoids and cytokines depends on the type of mediators. 
Human monocytes exposed to leukotrienes (e.g. LTB
4
) re-
lease high amounts of TNF-α (17). On the contrary, ad-
dition of PGE
2
 strongly inhibited the release of TNF-α 
by macrophages (18). An enhancing role of leukotrienes 
on production of IL-1 and IL-6 was also advocated (19). 
The n-3 derived eicosanoids (Fig. 1) have less inflamma-
tory or even anti-inflammatory effects; hence increasing 
dietary n-3 PUFAs would shift the balance of the eico-
sanoids formed to a less potent mixture in causing biologi-
cal response. For instance, fish oil supplementation of the 







 and 5-hydroxyeicosapentaenoic acid by inflamma-
tory cells (20). The functional significance of this is that 
LTB
5
 formed from EPA is 10–100-fold less potent as a neu-
trophil chemotactic agent than LTB
4
 derived from AA (21), 
while PGE
3
 is a less potent inducer of cyclooxygenase-2 
gene expression in fibroblasts, and of IL-6 production by 
macrophages than PGE
2
 (22). The third 20-carbon PUFA - 
dihomo-γ-linolenic acid (DGLA) belongs to the n-6 family, 
but inspite of this, DGLA derived eicosanoids (such as PG 
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IL-6r, IL-10, TGF–β) independently on confounders. The 
mechanisms responsible for the modulation of cytokine 
production by EPA and/or DHA remain unclear, although 
this mechanism could include suppression of eicosanoid 
production by n-3 PUFAs, based on the link between eico-
sanoids and cytokines.
Low-grade chronic inflammation is characterized by 
the same inflammatory mediators as an acute infection; 
however their levels are lower and the biologic response to 
a given cytokine may differ between acute and chronic in-
flammatory states. Multiple mechanisms may account for 
series 1) have lower biological activity that its AA derived 
homologues. Similar to EPA, DGLA may reduce the pro-
duction and efficacy of AA derivatives.
Besides direct effect on eicosanoids synthesis, EPA re-
duces the production of pro-inflammatory cytokines IL-1 
and IL-6, as well as TNF-α and –β in response to an in-
flammatory stimulus (23). In a community-based sample 
Ferrucci et al. have found (24) that  total n-3 PUFAs in 
plasma were independently associated with lower levels 
of proinflammatory markers (IL-6, IL-1ra, TNF-α, CRP) 
and higher levels of anti-inflammatory markers (soluble 
Figure 1. Dietary sources and simplifi ed metabolism of n-3 and n-6 PUFAs
COX- cyclooxygenase, LOX-lipoxygenase (Source: Vučić V, Ristić-Medić D.  Eicosapentaenoic Acid: Th e Role in Malignant Diseases. In 
Eicosapentaenoic Acid: Sources, Health Eff ects and Role in Disease Prevention. Editors: Th eodore G. Bradley and Francisco P. Vargas. 
ISBN: 978-1-62257-480-3 Nova Science Publishers, Inc. pp 99-116, 2012. with written permission from the publisher).
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this variability, including differences in plasma cytokine/
eicosanoid concentration, presence and concentration of 
soluble cytokine receptors and receptor antagonists, bal-
ance of pro- versus anti-inflammatory cytokine networks, 
and presence of bacterial cell wall products (25).  
PUFAs STATUS IN SERBIAN POPULATION
Since AA and EPA are crucial precursors for biosynthe-
sis of eicosanoids, they have important roles in inflamma-
tion. Arachidonic acid is the most important fatty acid in 
production of inflammatory mediators. Although it can be 
ingested from meat, eggs or dairy products, AA is most-
ly produced from its precursor LA. Namely, comparison 
of fatty acid composition in vegetarians and omnivorous 
humans showed relatively small differences in AA level in 
plasma phospholipids (12.8% vs. 11.1%) and cholesteryl es-
ters (7.8% vs. 6.5%), indicating that animal products in the 
diet increase the percentage of AA moderately (26).
In addition to reduced dietary intake of n-6 PUFAs, AA 
level in circulation can be decreased by an increased in-
take of EPA. The richest food sources of EPA are oily fish 
(tuna, salmon, mackerel, herring, and sardine) and fish oil 
(27). One fish oil capsule (1g) provides about 180 mg EPA+ 
120 mg DHA, while one oily fish meal can provide between 
1.5 and 3.5 g EPA+DHA (27). Another way to obtain n-3 
PUFA is metabolism of ALA to its longer chain and more 
unsaturated forms, including EPA, docosapentaenoic acid 
(DPAn-3, 22:5n-3) and DHA. However, the efficacy of this 
conversion is not very high and depends on the intake of 
LA, since both ALA and LA compete for the same elon-
gase/desaturase enzymes. Even though ALA is the pre-
ferred substrate, it is the most rapidly oxidized among all 
dietary PUFAs studied in humans; therefore conversion 
of dietary ALA to EPA is limited.  Accordingly, Brenna 
et al. reported that supplementation of the diet with high 
amounts of ALA led to small but significant increases in 
EPA and DPA, that was ascribed to increased oxidation of 
ALA, while supplementation with preformed EPA was ap-
proximately 15-fold more efficacious in this regard (28). 
In countries with low dietary intake of oily fish, levels 
of n-3 PUFAs in plasma phospholipids are generally low. 
Together with high dietary intake of LA from sunflower oil 
in our population, the n-6/n-3 ratio became unfavorable. 
Proportions of plasma n-3 and n-6 PUFAs in apparently 
healthy Serbian population with regard to their gender and 
age, are summarized in Table 1.
As it can be seen from Table 1, there are small differenc-
es in plasma phospholipids PUFAs among healthy Serbian 
people. Proportions of LA, AA and n-6 PUFAs are high, 
and levels of all n-3 PUFAs are very low; thus the n-6/n-3 
ratio is very high as well. A particularly high n-6/n-3 ratio 
was found in young males (29), while the lowest ratio was 
reported in middle-age population (32). In comparison, 
proportion of LA and AA in apparently healthy population 
from UK and Canada showed similar results as the studies 
from our country, but percentage of EPA ranged 1.2-1.5% 
of total fatty acids (33, 34), unlike 0.3-0.4% in Serbia. Thus 
the n-6/n-3 ratio in these studies ranged 4.95-5.50, while in 
our country it exceeded 10.
ROLE AND STATUS OF PUFAs IN LOW-GRADE 
INFLAMMATION
A number of studies have investigated possible mecha-
nisms in PUFAs modulation of the inflammatory response, 
but the data are often inconsistent. Beneficial anti-inflam-
matory effects of fish oil supplementation have been found 
in patients with active inflammation diseases such as rheu-
matoid arthritis and Crohn’s disease (4), but also in patients 
with cancers (35) or cardiovascular disease (36). Since IL-1 
and TNF are principal mediators of inflammation, reduced 










LA 26.72±2.54 25.9±3.5 28.39±2.81 27.89±2.48 26.47 ± 2.78
DGLA 2.96±0.72 2.7±1.0 2.71±0.84 2.66±0.68 2.42 ± 0.71
AA 12.74±2.14 11.2±2.0 12.41±2.20 10.96±1.60 11.56 ± 2.32
DTA 0.66±0.21 0.3±0.2 0.86±0.38 0.56±0.15 0.39 ± 0.19
n-6 43.08±3.04 40.4±3.9 44.27±1.80 41.51±2.47 40.84 ± 2.86
ALA n.a. n.a. n.a. 0.11±0.10 n.a.
EPA 0.35±0.22 0.3±0.2 0.41±0.24 0.28±0.21 0.36 ± 0.14
DPA 0.72±0.14 0.6±0.1 0.71±0.16 0.59±0.19 0.57 ± 0.10
DHA 3.11±1.01 3.6±1.1 3.84±1.06 3.26±1.33 3.63 ± 1.12
n-3 4.18±1.18 4.5±1.3 4.96±1.28 4.58±1.88 4.56 ± 1.35
n-6/n-3 11.15±3.36 9.6±2.3 9.47±2.39 10.76±4.89 8.82 ± 1.58
Table 1. Plasma phospholipids fatty acid composition (mol %) with reference to apparently healthy male (M) and female (F) Serbian population
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production of these cytokines may contribute to the ame-
lioration of inflammatory symptoms in patients taking n-3 
supplementation. Dietary supplementation with n-3 PUFAs 
in healthy subjects resulted in reduced levels of proinflam-
matory cytokines (IL-1, IL-2, PGE
2
 and thromboxane 2) and 
decreased mononuclear cell proliferation (37). Preclinical 
studies indicated that decreased generation of proinflam-
matory cytokines is a consequence of altered gene expres-
sion, including transcriptional down-regulation and sup-
pressed cyclooxygenase-2 activity (4). One of the possible 
mechanisms of n-3 PUFAs impact on inflammatory gene 
expression is modification of the activities of transcription 
factors. Two transcription factors that are likely involved 
in inflammation are nuclear factor κ B (NFκB) and peroxi-
some proliferator activated receptor (PPAR). There are 4 
isoforms of PPAR: α, β, δ and γ, and EPA has been found 
to bind and activate at least PPAR-α and -γ isoforms. The 
PPAR-α is expressed in many types of human cells, includ-
ing atherosclerotic plaques macrophages, while PPAR-γ is 
expressed in the immune cells (lymphocytes, monocytes, 
and macrophages), dendritic and many other cells (38). 
NFκB has been shown to up-regulate inflammatory cyto-
kines (TNF-α, IL-6, IL-1), adhesion molecules and COX-2 
genes. On the contrary, PPAR reduces inflammatory gene 
expression, and also interferes with the activation of NFκB 
(39). Namely, the NFκB is activated by protein kinase C cat-
alized phosphorylation, and subsequent dissociation of its 
inhibitory subunit. However, n-3 PUFAs have been shown 
to directly inhibit protein kinase C, and thereby decrease 
NFκB activation (38). Furthermore, NFκB can be inhibited 
by directly binding to PPAR-γ, which is activated by n-3 
PUFAs. In vitro studies have also documented decreased 
activation of NFκB in response to different inflammatory 
stimuli after treatment with EPA (40). These data are clini-
cally significant, because reduced NFκB and consequently 
reduced IL-1 and IL-6 in circulation will result in decreased 
production of CRP, which is related to the cardiovascular 
disease events and their severity (41).
PUFAs status is therefore essential in development of 
chronic non-communicable diseases. In addition to dietary 
intake, PUFAs status depends on metabolic processes in the 
body, which are often altered in inflammation. The results 
in Serbian patients with  chronic diseases showed that lev-
els of n-3 and n-6 PUFAs in plasma phospholipids, as well 
as their ratio were usually  altered: the n-6/n-3 ratio ranged 
from 11.2 in diabetic patients (42) to 15.4 in patients with 
non-Hodgkin’s lymphoma (NHL) (30). Moreover, we have 
recently found that the n-6/n-3 ratio in NHL patients var-
ied in response to chemotherapy from 8.5 in patients in re-
mission, to even 19.3 in patients with progression of NHL 
(43). These results are in accordance with a study by Xia et 
al. who showed that elevated n-6/n-3 PUFAs ratio stimu-
lated carcinogenesis, tumor growth and metastasis (44). 
Besides chronic non-communicable diseases, low grade 
systemic inflammation is found in elite athletes engaged 
in prolonged, intensive trainings. Although regular moder-
ate exercise has beneficial impact on health, chronic severe 
physical activity induces increased levels of cytokine and ei-
cosanoids in circulation. For this reason, altered PUFA pro-
files are expected in elite athletes, as presented in Table 2. 
The n-6/n-3 ratio in all tested Serbian athletes is relatively 
high, especially in boxers. Interestingly, these sportsmen 
do not have high levels of n-6 PUFAs (which are even lower 
than in the other athletes), but very low proportion of n-3 
PUFAs. Athletes engaged in heavy training programs ap-
pear to be more susceptible to infections than sedentary 
population due to a depression of immune system func-
tion, which could be explained by unfavorable PUFAs ratios 
(45). Based on these results, nutritional intervention and 
n-3 supplementation in all sport groups is recommended, 
and in boxers both n-6 and n-3 PUFAs intake should be 
markedly increased. 













Age (y) 21± 4 24±5 22.4±3.3 21.7±4.5 21.2±2.5 
LA 25.67±2.50 26.00±2.85 23.03±2.63 25.60±3.02 25.06±2.04
DGLA 3.32±0.85 3.24±0.67 2.26±0.48 2.76±0.78 2.46±0.65
AA 13.98±1.92 12.64±1.66 9.29±1.72 12.44±1.89 11.50±1.25
DTA 0.93±0.28 0.61±0.13 0.64±0.33 0.71±0.25 0.61±0.24
n-6 43.90±2.16 42.49±2.33 35.20±3.47 41.51±2.47 39.63±1.90
ALA n.a. n.a. n.a. 0.15±0.12 0.14±0.10
EPA 0.47±0.20 0.39±0.11 0.29±0.19 0.36±0.26 0.30±0.20
DPA 0.79±0.18 0.73±0.14 0.47±0.23 0.77±0.30 0.66±0.19
DHA 3.05±0.85 3.10±0.73 1.60±0.85 3.30±1.34 2.68±0.73
n-3 4.31±0.99 4.22±0.81 2.36±1.07 4.58±1.88 3.78±0.98
n-6/n-3 10.66±2.26 10.17±1.98 17.77±8.04 10.76±4.89 11.13±2.78
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DIETARY RECOMMENDATION
In spite of convincing evidence of a relationship between 
PUFAs intake and development of chronic diseases, only a 
sparse amount of human data is available for establishing 
a precise quantitative estimate of the n-3 and n-6 PUFAs 
requirement to prevent deficiency and provide optimal in-
take. According to the FAO/WHO report from 2008, the 
adequate intake to prevent deficiency is 2.5–3.5% of total 
energy intake (%E), while the minimum intake levels for 
EFA should be 2.5 % LA plus 0.5 % ALA (46). However, 
an effective intake for the prevention of chronic diseases 
is considered to be 6–11 % E (47). In addition, 0.250-2.0g 
of EPA+DHA daily should be included in the diet (46). In 
order to improve the n-6/n-3 ratio, it will be necessary to 
decrease the intake of n-6 PUFAs from vegetable oils and 
to increase the intake of n-3 PUFAs by using oils rich in 
ALA, increase the intake of oily fish to 2-3 times per week 
or take n-3 supplements. 
CONCLUDING REMARKS
Unhealthy diet with an imbalanced proportion of daily 
intake of n-3 and n-6 PUFAs is the main cause of low-grade 
systemic inflammation, which leads to the development of 
chronic diseases. The balanced intake of all fatty acids, par-
ticularly with regard to n-6/n-3 ratio, may help to prevent 
and reduce the chronic inflammation and diseases.
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